StreetAlpha.app
Home › Stocks › SPRO

Spero Therapeutics, Inc. (SPRO)

Healthcare
$0.90
▼ −3.28%
LAST CLOSE · NOV 17

Spero Therapeutics develops tebipenem HBr, an oral antibiotic in development for complicated urinary tract infections in adults. It last closed at $0.90 on Nov 17, down 3.28% on the day. The average 12-month price target from 2 analysts is $6.00 (+565.7% from the last close), with a high of $6.00 and a low of $6.00.

AI Auto Pilots
Is SPRO in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$41.6M
+2.5% vs a year ago
Net income
−$29.5M
−71.0% margin
EPS (diluted)
−$0.50
Operating margin
−67.3%
−$28.0M operating income
Valuation
Market cap
$52.5M
58.3M shares
P/E
–
No P/E while losing money
Price to sales
1.3
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$107.9M
At Sep 30
Shareholder equity
$781K
Shares outstanding
58.3M
At Nov 6
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $18.3M$18.3MFY2021FY2022: $53.5M$53.5MFY2022FY2023: $103.8M$103.8MFY2023FY2024: $48.0M$48.0MFY2024FY2025: $66.8M$66.8MFY2025

From SPRO's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Last report
Nov 12
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated SPRO in the past 90 days, not enough for a consensus
Average 12-month target
$6.00
▲ 565.7% upside

Based on 2 analysts who set a price target on SPRO in the past 90 days. The average target is $6.00, with a high of $6.00 and a low of $6.00, compared with the last close of $0.90.

Low $6.00Avg $6.00High $6.00
Blue marker: last close $0.90
Highest target$6.00
Average target$6.00
Lowest target$6.00
Latest rating changes
Cantor FitzgeraldInitiated
Oct 28Buy$6
HC Wainwright & Co.Maintained
Sep 14Buy$6
DateFirmActionRatingPrice target
Oct 28Cantor FitzgeraldInitiatedBuy$6
Sep 14HC Wainwright & Co.MaintainedBuy$6
Loading…

Technical Analysis

SPRO · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 17% below its 20 day and 25% below its 50 day average. It is 111% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 32), near oversold. The nearest support is the 52 week low at $0.88, and the nearest resistance the Pivot at $0.91.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 7.2%/day
Key levels
$3.0852 week high+242.2%
$1.90200 day average+111.1%
$1.29100 day average+43.3%
$1.18Swing high (Oct 28)+31.1%
$1.1350 day average+25.6%
$1.0520 day average+16.7%
$0.93Pivot R1+3.3%
$0.91Pivot+1.1%
$0.90Last close
$0.8852 week low−2.2%
$0.88Pivot S1−2.2%
Indicators
RSI (14)31.65Weak, oversold below 30Neutral
MACD-0.05Below its signal lineBearish
Stochastic13.1Near the bottom of its rangeOversold
ADX (14)17.9No clear trend
Williams %R-92.9Oversold below −80, overbought above −20Oversold
CCI (20)-189.3Oversold below −100, overbought above 100Oversold
Rate of change−13.3%Change over 10 sessionsBearish
ATR (14)$0.07Typical daily range, 7.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for SPRO

What happened before

See how SPRO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow SPRO usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How SPRO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in SPRO in the last 90 days.

Loading…

See today’s whale options flow across the market →

SPRO Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲35 buying vs 28 selling
  • ▲Held by funds +7.5 pts
  • ▲Funds holding +1
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding6160+1.7%
In funds' top 1012−50.0%
Held by funds44.4%36.9%+7.5 pts
New / increased19 / 1621 / 17−7.9%
Reduced / sold out11 / 176 / 12+55.6%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See SPRO institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SPRO is in one of them and how their past SPRO trades turned out.

SPRO in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered SPRO in an article yet. Here's the latest on the wider market.

About Spero Therapeutics

Spero Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, that develops treatments for rare diseases and diseases with high unmet need. Its main product candidate is tebipenem HBr, an oral tablet antibiotic in development to treat complicated urinary tract infections in adults with limited oral treatment options. The company has no products approved for sale, and GSK is developing and commercializing tebipenem HBr under a license agreement. Its intended users are adult patients and the physicians who treat them.

Headquarters
Cambridge, MA